Local angiotensin II generation in the rat heart: Role of renin uptake

Circulation Research

Volumn 82, Issue 1, 1998, Pages 13-20

  Müller, Dominik N ^d   Fischli, Walter ^b   Clozel, Jean Paul ^b   Hilgers, Karl F ^d   Bohlender, Jürgen ^d   Ménard, Joël ^a   Busjahn, Andreas ^d   Ganten, Detlev ^d   Luft, Friedrich C ^c  

^a INSERM   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c FRANZ VOLHARD CLINIC   (Germany)

^d NONE

Author keywords

Angiotensin; Cardiac renin angiotensin system; Chymase like activity; Human renin; Transgenic rat

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; CAPTOPRIL; CHYMOSTATIN; CILAZAPRIL; REMIKIREN; RENIN;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR AUTOREGULATION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; HOMEOSTASIS; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0344431351     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.1.13     Document Type: Article

References (51)

1. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990;15:44-55.
2. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1-6.
3. Danser AHJ, Koning MM, Admiraal PJJ, Sassen LM, Derkx FHM, Verdouw PD, Schalekamp MADH. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992;263:H429-H437.
4. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res. 1991;68: 905-921.
5. Unger T, Gohlke P. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am J Cardiol. 1990;65:31-101.
6. Lindpaintner K, Jin M, Wilhelm MJ, Suzuki F, Linz W, Schoelkens BA, Ganten D. Intracardiac generation of angiotensin and its physiologic role. Circulation. 1988;77:18-23.
7. Fordis CM, Megorden JS, Ropchak TG, Keiser HR. Absence of renin-like activity in rat aorta and microvessels. Hypertension. 1983;5:635-641.
8. London M, Bing RF, Thurston H, Swales JD. Arterial wall uptake of renal renin and blood pressure control. Hypertension. 1983;5:629-634.
9. Thurston H, Swales JD, Bing RF, Hurst BC, Marks ES, Vascular renin-like activity and blood pressure maintenance in the rat: studies of the effect of changes in sodium balance, hypertension and nephrectomy. Hypertension. 1979;1:643-649.
10. Lindpaintner K, Jin MW, Niedermaier N, Wilhelm MJ, Ganten D. Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res. 1990;67:564-573.
11. Hilgers KF, Hilgenfeldt U, Veelken R, Muley T, Ganten D, Luft FC, Mann JF. Angiotensinogen is cleaved to angiotensin in isolated rat blood vessels. Hypertension. 1993;21:1030-1034.
12. Kato H, Iwai N, Inui H, Kimoto K, Uchiyama Y, Inagami T. Regulation of vascular angiotensin release. Hypertension. 1993;21:446-454.
13. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension, I: results of a 14-week trial. Anh Intern Med. 1984;144:1947-1953.
14. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frohlich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol. 1984;53:105-108.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Enel J Med. 1991;325:293-302.
16. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension. 1987:9:42-48.
17. Rousseau MF. Konstam MA, Benedict CR. Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers JM, Pouleur H. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotsnsin-converting enzyme inhibitor. Am J Cardiol. 1994; 73:488-493.
18. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of ELITE study investigators: randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet. 1997;349:747-752.
19. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F Ruf P, Hilgenfeldt U. Ganten U, Kaling M. Bachmann S, Fukamizu A, Mullins JJ, Murakami K. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A. 1992;89:7806-7810.
20. Wolny A, Clozel J-P, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-270.
22. Muller DN, Hilgers KF, Bohlender J, Lippoldt A, Wagner J, Fischli W, Ganten D, Mann JF, Luft FC. Effects of human renin in the vasculature of rats transgenic for human angiotensinogen, Hypertension. 1995;26:272-278.
23. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol. 1993;62:207-210.
24. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
25. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science. 1996;271:502-505.
26. Balcells E, Meng QC, Hageman GR, Palmer RW, Durand JN, Dell'Italia LJ. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol. 1996;271;H417-H421.
27. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89:493-498.
28. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH, Renin is not synthesized by cardiac and extrarenal vascular tissues: a review of experimental evidence. Circulation. 1994;89:458-470.
29. Ruzicka M, Yuan B, Harmsen E, Leenen FH. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats: effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation. 1993;87:921-930.
30. Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensinaldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol, 1995;76:18D-23D.
31. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens. 1991;9:3-15.
32. Bohlender J, Ménard J, Luft FC, Ganten D. Effects of human renin in rats transgenic for human angiotensinogen. Hypertension. 1997;29:1031-1038.
33. Cumin F, Le-Nguyen D, Castro B, Ménard J, Corvol P. Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates. Biochim Biophys Acta. 1987;913:10-19.
34. Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Ganten U, Dietz R, Menard J, Murakami K, Luft FC, Ganten D. High human renin hypertension in transgenic rats. Hypertension. 1997;29:428-434.
35. Danser AHJ, van-Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994;24: 37-48.
36. De Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Hypertension, 1997;29: 1240-1251.
37. Okamura T, Aimi Y, Kimura H, Murakami K, Toda N. Existence of renin in the endothelium of human artery. J Hypertens. 1992;10:49-53.
38. Campbell DJ, Valentijn AJ. Identification of vascular renin-binding proteins by chemical cross-linking: inhibition of binding of renin by renin inhibitors. J Hypertens. 1994;12:879-90.
39. Sealey JE, Catanzaro DF, Lavin TN, Gahnem F, Pitarresi T, Hu LF, Laragh JH. Specific prorenin/renin binding (ProBP): identification and characterization of a novel membrane site. Am J Hypertens. 1996;9:491-502.
40. Takahashi S, Inoue H, Fukui K, Miyake Y. Structure and function of renin binding protein. Kidney Int. 1994;1525-527.
41. Nguyen G, Decarue F, Berrou J, Rondeau E, Sraer J. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. 1990;50:1897-1903.
42. Maru I, Ohta Y, Murata K, Tsukada Y. Molecular cloning and identification of N-acyl-D-glucosamine 2-epimerase from porcine kidney as a renin-binding protein, J Biol Chem. 1996;271:16294-16299.
43. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-fomiing pathways in normal and failing human hearts. Circ Res. 1990; 66:883-890.
44. Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem. 1991;266:19192-19197.
45. Le-Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci U S A. 1987;84:364-367.
46. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.
47. Clozel JP, Hess P, Michael C, Schietinger K, Baumgartner HR. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension. 1991;18(suppl):55-59.
48. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction, and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?: results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
49. Okunishi H, Shiota N, Fukamizu A. Angiotensin antagonist, not ACE inhibitor, prevents neointima formation on injured canine arteries. J Hypertens, 1994;12(suppl 3):S132. Abstract.
50. Ide H, Itoh H, Tomita M, Murakumo Y, Kobayashi T, Maruyama H, Osada Y, Nawa Y. Cloning of the cDNA encoding a novel rat mast-cell proteinase, rMCP-3, and its expression in comparison with other rat mast-cell proteinases. Biochem J. 1995;311:675-680.
51. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.